Scott Robinson

  • +353 857072245

Delivery of Proangiogenic Drugs in Diabetes

Pancreatic islet cell transplantation is a promising strategy that has been used for treatment of Type 1 Diabetes, but current protocols are limited by poor long term graft survival and the need for immunosuppression. Cellular encapsulation can overcome these limitations, but in order to preserve islet cell viability a robust blood supply to the graft is needed. Technologies developed through DAD will be used to deliver growth factors to implant sites to promote new blood vessel growth and thereby improve survival of encapsulated cells. Diabetic patients also have impaired wound healing, therefore we will also modify the growth factor delivery platform developed in DAD to improve healing in diabetic wounds.